Melvin Chua: This is an important consideration for current and future trials designs

Melvin Chua, Head of the Department of Head Neck and Thoracic Cancers, Division of Radiation Oncology at National Cancer Centre Singapore, shared on X/Twitter:

”EBVDNA is an archetypal liquid biopsy in endemic NPC Several trials+NRGHN001 Nancy Lee stratifies patients based on post-RT EBVDNA. We show that this is dynamic and time point matters! This is an important consideration for current and future trials designs!

We found that 2/3 of patients who were deemed to be EBVDNA+ at 0-2w post-RT actually cleared by 8-12w.

And the outcomes for this group is in fact comparable to the patients who were EBVDNA 0 at both time points.”

For the article click here.
Source: Melvin Chua/X